Abraxane, the first FDA-approvedchemotherapy incorporating albumin into its formulation, is indicatedfor locally advanced or metastatic NSCLC, while Genexol-PM is approvedin South Korea for the treatment of NSCLC.5,14. Here, ALB is linked to non-small cell lung carcinoma.